Oligometastatic Cancers and SBRT
The purpose of this educational lecture will be to review recent data on treatment of oligometastases, and to discuss practical approaches to treatment at different locations.
The activity is designed to meet the interests of radiation oncologists, radiation oncology residents and medical and clinical physicists.
Upon completion of this activity, participants should be able to do the following:
- Understand the evidence supporting the existence of an oligometastatic state.
- Be aware of new randomized data assessing the use of ablative therapies in the treatment of metastases.
- Have a safe approach to treatment of oligometastases in practice.
David Palma, MD, MSc, PhD, is employed by London Health Sciences Center and has received honoraria from Need Inc and UptoDate.com. He has stock ownership in Need Inc.
All relevant financial relationships have been mitigated.
The person(s) above served as the developer(s) of this activity. Additionally, the Annual Refresher Course Planning Committee had control over the content of this activity.
The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council of Continuing Medical Education to provide continuing education to physicians.
ASTRO is awarded Deemed Status by the American Board of Radiology to provide SA-CME as part of Part II Maintenance of Certification.
- 1.25 AMA PRA Category 1 Credit™The American Society for Radiation Oncology (ASTRO) is accredited by the Accreditation Council for Continuing Medical Education for physicians. ASTRO designates this for a maximum of 1.25 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
- 1.25 Certificate of AttendanceThis activity was designated for 1.25 AMA PRA Category 1 Credit™.
One of the two latest versions of Google Chrome, Mozilla Firefox, Internet Explorer or Safari.